QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS5-Region Domestic Shipping
What is Mazdutide?
Mazdutide (IBI362 — Dual GLP-1R/GCGR agonist (approved China 2024)) is a Weekly injectable fatty acid-conjugated peptide. Weekly injectable dual GLP-1R/GCGR agonist approved in China (2024) — same receptor pairing as survodutide, distinct molecule. GLORY Phase 3: ~10–14% weight reduction, HbA1c reduction in T2D. First dual GLP-1R/GCGR agonist with national approval.
Research Applications
Approved Reference Compound
China-approved dual GLP-1R/GCGR — Phase 3 efficacy data reference
vs Survodutide
Same receptor pair, different pharmacology — comparative research
T2D + Obesity Models
GLORY Phase 3 data: HbA1c and weight reduction combined endpoints
GCGR Thermogenesis
Glucagon-mediated fat oxidation alongside GLP-1R appetite suppression
Weekly Dosing PK
Long-acting fatty acid-conjugated peptide pharmacokinetics
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 2259884‑03‑0 |
| Molecular Formula | C₂₁₀H₃₂₂N₄₆O₆₇ |
| Peptide Type | Dual Glucagon‑Like Peptide‑1 (GLP‑1) and Glucagon Receptor Agonist |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months unopened |




